Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

A Randomized Study Comparing Video-Based Mindfulness-Based Cognitive Therapy With Video-Based Traditional Cognitive Behavioral Therapy in a Sample of Women Struggling to Achieve Orgasm.

Adam F, De Sutter P, Day J, Grimm E.

J Sex Med. 2019 Dec 6. pii: S1743-6095(19)31518-8. doi: 10.1016/j.jsxm.2019.10.022. [Epub ahead of print]

PMID:
31818723
2.

Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma.

Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE.

Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4187-4195. doi: 10.1167/iovs.19-28082.

3.

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors.

Saif MW, Rajagopal S, Caplain J, Grimm E, Serebrennikova O, Das M, Tsichlis PN, Martell R.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1323-1331. doi: 10.1007/s00280-019-03967-3. Epub 2019 Oct 3.

PMID:
31583436
4.

TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.

Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R.

Cancer Immunol Immunother. 2019 Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9.

PMID:
31501955
5.

Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis.

Sceats LA, Ku S, Coughran A, Barnes B, Grimm E, Muffly M, Spain DA, Kin C, Owens DK, Goldhaber-Fiebert JD.

MDM Policy Pract. 2019 Aug 17;4(2):2381468319866448. doi: 10.1177/2381468319866448. eCollection 2019 Jul-Dec.

6.

Localized bursting of mesocarp cells triggers catastrophic fruit cracking.

Grimm E, Hahn J, Pflugfelder D, Schmidt MJ, van Dusschoten D, Knoche M.

Hortic Res. 2019 Jun 22;6:79. doi: 10.1038/s41438-019-0161-3. eCollection 2019.

7.

Sweet Cherry Fruit: Ideal Osmometers?

Winkler A, Grimm E, Knoche M.

Front Plant Sci. 2019 Mar 5;10:164. doi: 10.3389/fpls.2019.00164. eCollection 2019.

8.

Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.

McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL Jr, Grimm EA, Lazar AJ, Woodman SE.

J Invest Dermatol. 2019 Mar;139(3):728-731. doi: 10.1016/j.jid.2018.10.009. Epub 2018 Oct 25. No abstract available.

PMID:
30798855
9.

High-Throughput Architecture for Discovering Combination Cancer Therapeutics.

Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00054.

10.

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.

Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA.

Clin Cancer Res. 2019 Mar 1;25(5):1650-1663. doi: 10.1158/1078-0432.CCR-18-1163. Epub 2018 Dec 11.

PMID:
30538110
11.

Accumulation of metals and polycyclic aromatic hydrocarbons in agricultural soil after additions of street sediment in southern Ontario.

McDonough A, Baker S, Grimm E, Todd A, Luciani M, Terry D.

J Environ Manage. 2019 Feb 15;232:545-553. doi: 10.1016/j.jenvman.2018.11.049. Epub 2018 Nov 29.

PMID:
30503901
12.

Mitochondrial dynamic alterations regulate melanoma cell progression.

Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H.

J Cell Biochem. 2018 Sep 6. doi: 10.1002/jcb.27518. [Epub ahead of print]

PMID:
30256441
13.

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00055. Epub 2018 Jun 5. No abstract available.

14.

Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy.

Kim SH, Roszik J, Grimm EA, Ekmekcioglu S.

Front Oncol. 2018 Mar 16;8:67. doi: 10.3389/fonc.2018.00067. eCollection 2018. Review.

15.

Clinicopathologic analysis of a large series of microinvasive breast cancers.

Lillemoe TJ, Tsai ML, Swenson KK, Susnik B, Krueger J, Harris K, Rueth N, Grimm E, Leach JW.

Breast J. 2018 Jul;24(4):574-579. doi: 10.1111/tbj.13001. Epub 2018 Feb 24.

PMID:
29476574
16.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

17.

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J.

Front Immunol. 2017 Jun 16;8:689. doi: 10.3389/fimmu.2017.00689. eCollection 2017.

18.

Physical rupture of the xylem in developing sweet cherry fruit causes progressive decline in xylem sap inflow rate.

Grimm E, Pflugfelder D, van Dusschoten D, Winkler A, Knoche M.

Planta. 2017 Oct;246(4):659-672. doi: 10.1007/s00425-017-2719-3. Epub 2017 Jun 16.

PMID:
28623562
19.

A tool for discovering drug sensitivity and gene expression associations in cancer cells.

Qin Y, Conley AP, Grimm EA, Roszik J.

PLoS One. 2017 Apr 28;12(4):e0176763. doi: 10.1371/journal.pone.0176763. eCollection 2017.

20.

Pathologic Predictors of Treatment Response to Neo-adjuvant Chemotherapy for Invasive Lobular Breast Carcinoma.

Tsai M, Finkelstein M, Lillemoe T, Susnik B, Grimm E, Kang SH, Kelly C, Swenson K.

Breast J. 2017 Sep;23(5):607-609. doi: 10.1111/tbj.12809. Epub 2017 Mar 22. No abstract available.

PMID:
28328042
21.

Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.

Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW.

Neoplasia. 2017 Mar;19(3):237-249. doi: 10.1016/j.neo.2016.07.009.

22.

Targeting iNOS to increase efficacy of immunotherapies.

Ekmekcioglu S, Grimm EA, Roszik J.

Hum Vaccin Immunother. 2017 May 4;13(5):1105-1108. doi: 10.1080/21645515.2016.1276682. Epub 2017 Jan 25.

23.

Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.

Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C.

Melanoma Res. 2017 Apr;27(2):126-133. doi: 10.1097/CMR.0000000000000329.

PMID:
28118269
24.

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L.

Cancer Immunol Res. 2016 Nov;4(11):983-994. Epub 2016 Oct 3.

25.

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.

Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J.

Sci Rep. 2016 Oct 20;6:35848. doi: 10.1038/srep35848.

27.

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA.

Mol Cancer Ther. 2016 Oct;15(10):2442-2454. Epub 2016 Jul 25.

28.

Uveal melanoma: From diagnosis to treatment and the science in between.

Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP.

Cancer. 2016 Aug 1;122(15):2299-312. doi: 10.1002/cncr.29727. Epub 2016 Mar 15. Review.

29.

Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.

Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA.

Medicine (Baltimore). 2016 Mar;95(11):e3073. doi: 10.1097/MD.0000000000003073.

30.

Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.

Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2016 May;29(3):297-308. doi: 10.1111/pcmr.12455. Epub 2016 Mar 15.

31.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

32.

IL-10: Expanding the Immune Oncology Horizon.

Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB.

Receptors Clin Investig. 2015;2(4). pii: 1041. Epub 2015 Nov 4.

33.

Best available technology for European livestock farms: Availability, effectiveness and uptake.

Loyon L, Burton CH, Misselbrook T, Webb J, Philippe FX, Aguilar M, Doreau M, Hassouna M, Veldkamp T, Dourmad JY, Bonmati A, Grimm E, Sommer SG.

J Environ Manage. 2016 Jan 15;166:1-11. doi: 10.1016/j.jenvman.2015.09.046. Epub 2015 Oct 24. Review.

PMID:
26468602
34.

Dual Roles of RNF2 in Melanoma Progression.

Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L.

Cancer Discov. 2015 Dec;5(12):1314-27. doi: 10.1158/2159-8290.CD-15-0493. Epub 2015 Oct 8.

35.

Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.

Tsai ML, Lillemoe TJ, Finkelstein MJ, Money JE, Susnik B, Grimm E, Kang SH, Swenson KK.

Clin Breast Cancer. 2016 Feb;16(1):45-50. doi: 10.1016/j.clbc.2015.08.001. Epub 2015 Aug 19.

PMID:
26385397
36.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2901. doi: 10.1038/jid.2015.259. Epub 2015 Jul 16. No abstract available.

37.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2775-2784. doi: 10.1038/jid.2015.204. Epub 2015 Jun 3. Erratum in: J Invest Dermatol. 2015 Nov;135(11):2901.

38.

Red blood cell transfusion practices: a College of American Pathologists Q-Probes study of compliance with audit criteria in 128 hospitals.

Ramsey G, Wagar EA, Grimm EE, Friedberg RC, Souers RJ, Lehman CM.

Arch Pathol Lab Med. 2015 Mar;139(3):351-5. doi: 10.5858/arpa.2013-0756-CP.

PMID:
25724032
39.

Inflammatory IL-1β-driven JNK activation in stage III melanoma.

Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2015 Mar;28(2):236-9. doi: 10.1111/pcmr.12348. Epub 2015 Jan 12. No abstract available.

PMID:
25546243
40.

Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.

Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE.

Pigment Cell Melanoma Res. 2015 May;28(3):357-9. doi: 10.1111/pcmr.12345. Epub 2015 Mar 23. No abstract available.

PMID:
25515650
41.

4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.

Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q.

Melanoma Res. 2016 Apr;26(2):181-7. doi: 10.1097/CMR.0000000000000106.

42.

Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.

Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V.

Transl Oncol. 2014 Aug;7(4):484-92. doi: 10.1016/j.tranon.2014.05.008. Epub 2014 Jun 23.

43.

Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.

Chattopadhyay C, Grimm EA, Woodman SE.

PLoS One. 2014 Feb 13;9(2):e83957. doi: 10.1371/journal.pone.0083957. eCollection 2014.

44.

Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.

Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG.

Cancer Res. 2014 Feb 15;74(4):1067-78. doi: 10.1158/0008-5472.CAN-13-0588. Epub 2014 Jan 7.

45.

Expression of leptin and iNOS in oral melanomas in dogs.

Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA.

J Vet Intern Med. 2013 Sep-Oct;27(5):1278-82. doi: 10.1111/jvim.12169. Epub 2013 Aug 26.

46.

Model systems for a no-analog future: species associations and climates during the last deglaciation.

Williams JW, Blois JL, Gill JL, Gonzales LM, Grimm EC, Ordonez A, Shuman B, Veloz SD.

Ann N Y Acad Sci. 2013 Sep;1297:29-43. doi: 10.1111/nyas.12226. Epub 2013 Aug 27.

PMID:
23981247
47.

Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Grimm EA, Sikora AG, Ekmekcioglu S.

Clin Cancer Res. 2013 Oct 15;19(20):5557-63. doi: 10.1158/1078-0432.CCR-12-1554. Epub 2013 Jul 18. Review.

48.

Intracuticular wax fixes and restricts strain in leaf and fruit cuticles.

Khanal BP, Grimm E, Finger S, Blume A, Knoche M.

New Phytol. 2013 Oct;200(1):134-43. doi: 10.1111/nph.12355. Epub 2013 Jun 10.

49.

Polymorphisms of nucleotide excision repair genes predict melanoma survival.

Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q.

J Invest Dermatol. 2013 Jul;133(7):1813-21. doi: 10.1038/jid.2012.498. Epub 2013 Feb 14.

50.

Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population.

Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q.

Pigment Cell Melanoma Res. 2013 May;26(3):422-5. doi: 10.1111/pcmr.12070. Epub 2013 Feb 19. No abstract available.

Supplemental Content

Support Center